Clofarabine for myelodysplastic syndromes

Bibliography

• Greenberg P, Cox C, LeBeau MM, International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88
   PubMed Web of Science ®Google Scholar
• Malcovati L, Germing U, Kuendgen A, Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25:3503-10
   PubMed Web of Science ®Google Scholar
• Tiu RV, Gondek LP, O'Keefe C, Prognostic Impact of SNP Array Karyotyping in Myelodysplastic Syndromes and Related Myeloid Malignancies. Blood 2010;117:4552-60
   Google Scholar
• Sekeres MA. Are we nearer to curing patients with MDS? Best Pract Res Clin Haematol 2010;23:481-7
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Gandhi V, Kozuch P, Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 2003;21:1167-73
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Gandhi V, Cortes J, Phase II clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003;102:2379-86
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Erba HP, Claxton D, Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 2010;28:549-55
   PubMed Web of Science ®Google Scholar
• Jeha S, Gaynon PS, Razzouk BI, Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 2006;24:1917-23
   PubMed Web of Science ®Google Scholar
• Burnett AK, Russell NH, Kell J, European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol 2010;28:2389-95
   PubMed Web of Science ®Google Scholar
• Faderl S, Garcia-Manero G, Estrov Z, Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. J Clin Oncol 2010;28:2755-60
   PubMed Web of Science ®Google Scholar
• Faderl S, Ravandi F, Huang X, A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008;112:1638-45
   PubMed Web of Science ®Google Scholar
• Clofarabine. Drugs R D 2004;5:213-17
   PubMedGoogle Scholar
• King KM, Damaraju VL, Vickers MF, A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems. Mol Pharmacol 2006;69:346-53
   PubMed Web of Science ®Google Scholar
• Xie C, Plunkett W. Metabolism and actions of 2-chloro-9-(2-deoxy-2-fluoro-beta-D- arabinofuranosyl)-adenine in human lymphoblastoid cells. Cancer Res 1995;55:2847-52
   PubMed Web of Science ®Google Scholar
• Xie KC, Plunkett W. Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine. Cancer Res 1996;56:3030-7
   PubMed Web of Science ®Google Scholar
• Genini D, Adachi S, Chao Q, Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria Blood 2000;96:3537-43
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhahriar M, Zhang J, Clofarabine induced hypomethylation of DNA and expression of Cancer-Testis antigens. Leuk Res 2009;33:1678-83
   PubMed Web of Science ®Google Scholar
• Waud WR, Schmid SM, Montgomery JA, Secrist JA 3rd. Preclinical antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D- arabinofuranosyl)adenine (Cl-F-ara-A). Nucleosides Nucleotides Nucleic Acids 2000;19:447-60
   PubMed Web of Science ®Google Scholar
• Takahashi T, Kanazawa J, Akinaga S, Antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine, a novel deoxyadenosine analog, against human colon tumor xenografts by oral administration. Cancer Chemother Pharmacol 1999;43:233-40
   PubMed Web of Science ®Google Scholar
• Bonate PL, Arthaud L, Cantrell WR Jr, Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat Rev Drug Discov 2006;5:855-63
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kantarjian H, World Health Organization (WHO) international working group. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000;96:3671-74
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kopecky KJ, Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003;21:4642-9
   PubMed Web of Science ®Google Scholar
• Lim S, McMahan J, Zhang J, Zhang Y. A Phase II study of low dose intravenous clofarabine for elderly patients with myelodysplastic syndrome who have failed 5-azaytidine. Leuk Lymphoma 2010;51:2258-61
   PubMed Web of Science ®Google Scholar
• Faderl S, Gandhi V, O'Brien S, Results of a Phase I-II study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 2005;105:940-7
   PubMed Web of Science ®Google Scholar
• Sekeres MA, Roboz GJ, Odenike O, Preliminary results of fixed-dose oral clofarabine (Clo) in patients WHO have failed hypomethylating agents for the treatment of myelodysplastic syndromes (MDS). 52nd Annual American Society of Hematology Meeting Abstract 1869
   Google Scholar
• Mineishi S, Magenau J, Tobai H, Allogeneic hematopoietic stem cell transplantation with clofarabine/busulfan x 4 (CloBu4) Conditioning Exhibits Significant Anti-Tumor Activity In Non - Remission Hematologic Malignancies, Especially In AML. 52nd Annual American Society of Hematology Meeting Abstract 35
   Google Scholar
• Tiu RV, Gondek LP, O'Keefe C, New lesions detected by SNP array-based chromosomal analysis have important clinical impact in AML. J Clin Oncol 2009;27(31):5219-26
   PubMed Web of Science ®Google Scholar
• Jankowska AM, Szpurka H, Tiu RV, Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 2009;113:6403-10
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lim KH, Abdel-Wahab O, Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 2009;23:1343-45
   PubMed Web of Science ®Google Scholar
• Delhommeau F, Dupont S, Della Valle V, Mutation in TET2 in myeloid cancers. N Engl J Med 2009;360:2289-301
   PubMed Web of Science ®Google Scholar
• Langemeijer SM, Kuiper RP, Berends M, Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009;41:838-42
   PubMed Web of Science ®Google Scholar
• Makishima H, Jankowska AM, Tiu RV, Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies. Leukemia 2010;24:1799-804
   PubMed Web of Science ®Google Scholar
• Makishima H, Cazzolli H, Szpurka H, Mutations of E3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J Clin Oncol 2009;27:6109-16
   PubMed Web of Science ®Google Scholar
• Gelsi-Boyer V, Trouplin V, Roquain J, ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol 2010;151:365-75
   PubMed Web of Science ®Google Scholar
• Gelsi-Boyer V, Trouplin V, Adelaide J, Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2009;145:788-800
   PubMed Web of Science ®Google Scholar
• Szpurka H, Jankowska AM, Przychodzen B, UTX Mutations and Epigenetic Changes In MDS/MPN and Related Myeloid Malignancies. 52nd Annual American Society of Hematology Meeting Abstract 121
   Google Scholar
• Paschka P, Schlenk RF, Gaidzik VI, IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010;28:3636-43
   PubMed Web of Science ®Google Scholar
• Ley TJ, Ding L, Walter MJ, DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010;363:2424-33
   PubMed Web of Science ®Google Scholar
• Ko M, Huang Y, Jankowska AM, Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010;468:839-43
   PubMed Web of Science ®Google Scholar